Logan Reid
Clostridioides difficile, often referred to as C. difficile or C. diff, is a type of bacteria that can cause severe diarrhea and, in some cases, life-threatening colitis (inflammation of the colon). C. diff infections are more commonly associated with healthcare settings, such as hospitals and nursing homes, as the bacteria can persist in the environment and spread from person to person. The Centers for Disease Control and Prevention (CDC) plays a crucial role in tracking and preventing C. diff infections, with initiatives like the Emerging Infections Program and the National Healthcare Safety Network (NHSN). The CDC provides guidelines, resources, and training to healthcare facilities and staff to identify, report, and manage C. diff cases effectively, aiming to reduce the incidence and impact of this potentially deadly infection.
| Characteristics | Values |
|---|---|
| Full Form | CDI (Clostridioides difficile Infection) |
| C. diff | C. difficile or C. diff |
| Cause | C. diff is a germ that causes diarrhea and colitis (inflammation of the colon) |
| Occurrence | C. diff infection can affect anyone, but most cases occur when you’ve been taking antibiotics or soon after |
| Risk Factors | A weakened immune system, previous C. diff infection or exposure, recent medical care |
| Tracking | CDC tracks hospital C. diff cases through self-reported data from hospitals via the NHSN system |
| Surveillance | EIP site staff identify cases based on reports of positive C. difficile toxin or nucleic acid amplification assays |
| Prevention | Hand hygiene, dedicated patient equipment, daily bathing, environmental cleaning, antibiotic stewardship |
| Treatment | Maintain contact precautions, notify appropriate departments, assess testing appropriateness, implement laboratory procedures |
Explore related products
What You'll Learn
CDI surveillance guidelines
The CDC's Clostridioides difficile infection (CDI) Surveillance Program identifies and monitors CDI incidence and burden in communities and healthcare settings. CDI surveillance guidelines are provided by the CDC's National Healthcare Safety Network (NHSN), which is a secure, web-based surveillance system used by healthcare facilities across the United States. The NHSN provides standardized definitions for CDI, and the CDC offers an overview of NHSN surveillance protocols.
The CDI Surveillance Program collects data on the incidence and trends of CDI infections, which can be used by public health professionals and healthcare providers to further public health research and improve health outcomes. Trained professionals conduct active population- and laboratory-based surveillance in 10 EIP sites. EIP site staff identify cases based on reports of positive C. difficile toxin or nucleic acid amplification assays from clinical, reference, and commercial laboratories serving residents of the surveillance areas. They record information on additional positive specimens from the same patient to identify and track recurrent or duplicate episodes, as well as new cases.
To increase comparability between clinical settings, available standardized case definitions should be used for the surveillance of healthcare facility-onset (HO) CDI, community-onset, healthcare facility-associated (CO-HCFA) CDI, and community-associated (CA) CDI. At a minimum, surveillance for HO-CDI should be conducted in all inpatient healthcare facilities to detect elevated rates or outbreaks of CDI within the facility. The rate of HO-CDI can be expressed as the number of cases per 10,000 patient-days, while the CO-HCFA prevalence rate can be expressed as the number of cases per 1,000 patient admissions.
In the context of high endemic rates or outbreaks, data should be stratified by patient location to target control measures when CDI incidence exceeds national and/or facility reduction goals or if an outbreak is noted. For pediatric institutions, the same standardized case definitions and rate expressions should be used. Surveillance for HO-CDI in inpatient pediatric facilities is recommended, excluding cases under two years of age. Additionally, surveillance for CA-CDI can be considered to detect trends in the community.
Grey Sloan Memorial Hospital: Closure or Continuation?
You may want to see also
Explore related products
CDI case detection
Clostridioides difficile, often called C. difficile or C. diff, is a type of bacteria that can cause severe diarrhea and, in some cases, even lead to death. C. diff infection is more likely to occur in individuals who have recently taken antibiotics or are undergoing medical treatment. The infection is a common occurrence in healthcare settings, such as hospitals and nursing homes, due to the presence of C. diff carriers and the ease of germ transmission.
The Centers for Disease Control and Prevention (CDC) plays a crucial role in addressing this issue through its Clostridioides difficile Infection (CDI) Surveillance program. This program collects and analyzes data to understand the incidence and trends of C. diff infections. The CDC provides training to hospital staff on CDI case detection and tracking, utilizing its own CDI surveillance guidelines. Hospitals are responsible for self-reporting healthcare-associated infections (HAI) and Laboratory Identification (LabID) event data to the CDC via the National Healthcare Safety Network (NHSN), a secure web-based surveillance system.
EIP site staff play a vital role in CDI case detection. They identify cases based on reports of positive C. difficile toxin or nucleic acid amplification assays from various laboratories serving residents in surveillance areas. These staff members meticulously record information on additional positive specimens from the same patient, enabling them to identify recurrent or new cases. They also conduct a brief medical record review to gather demographic characteristics, the location of stool collection, and healthcare exposures.
In addition to EIP site staff efforts, CDI case detection is further strengthened by the collection of stool specimens from incident CDI cases. These specimens are sent to reference laboratories for culture, and the resulting C. difficile isolates are forwarded to the CDC for molecular typing and characterization. This comprehensive process ensures accurate identification and tracking of CDI cases, contributing to effective surveillance and public health interventions.
Circumcision Services: Hospitals and the Snip
You may want to see also
Explore related products
CDI prevention in acute care facilities
Clostridioides difficile, often called C. difficile or C. diff, is a type of bacteria that can cause severe diarrhea and, in some cases, even lead to death. C. diff infection, or CDI, is more commonly found in patients in healthcare settings, such as hospitals and nursing homes. This is because many people carrying C. diff receive treatment in these facilities. The bacteria spread from person to person through feces and can also be found in the environment.
The Centers for Disease Control and Prevention (CDC) provides clinical guidance for C. diff prevention in acute care facilities. Here are some strategies and interventions recommended by the CDC to prevent CDI in acute care settings:
Cleaning and Disinfection:
Patient care areas, including high-touch surfaces and the immediate vicinity around a CDI patient, should be cleaned and disinfected at least once daily. All shared equipment, such as toilets, wheelchairs, and gurneys, should be cleaned and disinfected prior to use by another patient. After a CDI patient is transferred or discharged, terminal cleaning with a C. difficile sporicidal agent (EPA List K agent) should be performed.
Isolation and Contact Precautions:
Nurse-driven protocols should be established to rapidly isolate patients with suspected or confirmed CDI. Patients with diarrhea should be isolated while the cause is being evaluated. Symptomatic patients should be placed on contact precautions in single-patient rooms with dedicated toilets. If single-patient rooms are unavailable, patients with confirmed CDI can be roomed together. Contact precautions should be maintained for at least 48 hours after diarrhea has resolved or for the duration of the patient's hospitalization.
Hand Hygiene and Room Cleaning:
Adherence to hand hygiene and contact precautions is crucial. Room cleaning should follow the methods described in "Options for Evaluating Environmental Cleaning" to ensure effectiveness.
Antibiotic Stewardship:
The facility's antibiotic stewardship program should be engaged. The appropriateness of prescribing antibiotics that pose the highest risk for CDI, such as fluoroquinolones, carbapenems, and 3rd and 4th generation cephalosporins, should be assessed. Facility-specific treatment recommendations for common infections should be developed, minimizing the use of high-risk antibiotics. Ensure that patients receive the shortest effective duration of antibiotic therapy.
Surveillance and Monitoring:
Acute care facilities should monitor their CDI rates and target units with the highest incidence for evaluation and intervention. Hospital-onset CDI cases should be reviewed to identify potential gaps and opportunities for improvement, focusing on areas such as test indications and antibiotic appropriateness.
Education and Training:
Healthcare personnel should be educated and trained on CDI prevention practices, including hand hygiene and contact precautions.
By following these strategies, acute care facilities can effectively prevent and control the spread of CDI, protecting both patients and healthcare providers.
Maria Parham Hospital: Trick-or-Treat?
You may want to see also
Explore related products
CDI treatment
Clostridioides difficile infection (CDI) is a type of bacteria that can cause severe diarrhea and, in some cases, death. CDI is often associated with antibiotic use, which can disrupt the normal intestinal flora, making individuals more susceptible to illnesses. CDI is more commonly found in healthcare settings, such as hospitals and nursing homes, where many infected individuals receive treatment or stay.
Regarding treatment, the Infectious Diseases Society of America's 2010 guidelines recommend oral metronidazole for mild cases of CDI. However, for more severe cases, oral vancomycin is preferred. Metronidazole's effectiveness in treating CDI has been questioned due to its inferiority to oral vancomycin in some studies. Vancomycin or fidaxomicin is considered a better choice for clinically significant CDI cases due to metronidazole's flawed pharmacokinetics. For patients unable to take oral medications, intravenous metronidazole is an option.
For recurrent CDI, the initial treatment drug can be repeated for the first recurrence. For subsequent recurrences, vancomycin can be administered in pulsed or tapered doses. New treatment modalities, such as bacteriotherapy and immunotherapy, show promise for recurrent CDI treatment.
Fecal microbiota transplantation (FMT) is a newer treatment option for CDI. FMT is recommended when antibiotics fail to resolve CDI or when CDI recurs. The procedure involves transferring healthy bacteria from a donor's stool into the patient's intestine to restore the balance of good bacteria. While FMT has shown promising results in reducing diarrhea and CDI recurrence, more research is needed to fully understand its short-term and long-term side effects.
In addition to the above treatments, probiotics are often recommended to be taken with antibiotics to prevent CDI recurrence. It is important to consult with a healthcare professional before taking any over-the-counter antidiarrheal medications, as they may worsen CDI symptoms. Discontinuing the antibiotics that predisposed the patient to CDI is an important part of therapy.
STD Testing: What Hospitals Routinely Check For
You may want to see also
Explore related products
CDI risk factors
Clostridioides difficile infection (CDI) is linked to many risk factors. While anyone can get a C. diff infection, most cases occur in individuals who have recently taken antibiotics or completed a course of antibiotics. Antibiotics can disrupt the natural intestinal flora, allowing bacteria to cause disease. People are up to 10 times more likely to get a C. diff infection while taking antibiotics or during the three months after, with longer courses potentially doubling their risk. Antibiotic use can also affect the microbiome, making individuals more susceptible to illnesses like C. diff.
Other risk factors include proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RA), advanced age, co-morbidities, exposure to healthcare settings, obesity, non-steroidal anti-inflammatory drugs (NSAIDs), vitamin D, and host genetics. According to the Infectious Disease Society of America (IDSA), CDI is considered community-acquired if the diagnosis was without exposure to a healthcare facility after 12 weeks of discharge, and hospital-acquired if diagnosed within three days of admission or within four weeks of release.
Healthcare facilities are at the highest risk of infection transmission due to the environment, surfaces, and healthcare worker contamination. Therefore, good hygiene among healthcare workers and surface disinfection are crucial to minimizing CDI transmission. CDI patients should also be isolated from other patients to prevent transmission.
In a 2015 study, the Centers for Disease Control and Prevention (CDC) estimated that C. difficile caused approximately 500,000 infections and 15,000 deaths each year in the United States. Nearly two-thirds of the estimated C. difficile infections were healthcare-associated, and 82% of all cases reported recent healthcare contact.
Transferring Hospitals: What You Need to Know
You may want to see also
Frequently asked questions
C. diff is short for Clostridioides difficile, a type of bacteria that can cause severe diarrhea and, in some cases, lead to fatal colitis (inflammation of the colon).
The CDC tracks C. diff through its Emerging Infections Program (EIP) and the National Healthcare Safety Network (NHSN). EIP site staff identify cases based on reports of positive C. diff toxin or nucleic acid amplification assays. They record information on additional positive specimens from the same patient to track recurrent or new cases. Hospitals also self-report healthcare-associated infections (HAI) and LabID event data to the CDC through the NHSN.
C. diff infections are more likely to occur in individuals who have recently taken antibiotics, have received medical care, or have a weakened immune system. Antibiotics can disrupt the natural intestinal flora, allowing C. diff bacteria to cause disease. The risk of infection is also higher in healthcare settings, such as hospitals and nursing homes, due to the presence of individuals carrying C. diff.
